Levels of Inflammatory Markers in the Treatment of Stroke—An SPS3 Ancillary Study "LIMITS"

Completed

Phase N/A Results N/A

Update History

26 Jul '17
The description was updated.
New
Inflammation is increasingly recognized as playing a central role in atherosclerosis and coronary artery disease. And, peripheral blood markers of inflammation have been associated with incident and recurrent cardiac events. The relationship of these risk markers—which have the potential to be modified—to prognosis after ischemic stroke is less clear. The Levels of Inflammatory Markers in the Treatment of Stroke (LIMITS) study will address questions about the role of inflammatory markers in secondary stroke prevention in a cost-effective manner using the well-established framework of the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. The SPS3 trial is an ongoing Phase 3, multicenter secondary stroke prevention trial that focuses on preventing stroke recurrence in people with small vessel ischemic stroke, or lacunes. The overall purpose of the LIMITS study is to determine if serum levels of inflammatory markers—such as hsCRP, serum amyloid A (SAA), CD40 ligand (CD40L), and monocyte chemoattractant protein-1 (MCP-1)—predict recurrent stroke and other vascular events among people with a history of small artery ischemic stroke. The project will also determine if these markers predict which people will respond best to dual antiplatelet therapy with clopidogrel and aspirin. The specific aims of LIMITS are to determine if hsCRP, SAA, CD40L, and MCP-1 levels are independent risk factors for recurrent ischemic stroke, and for recurrent ischemic stroke, myocardial infarction, and death in participants in the SPS3 trial after adjusting for demographic and traditional stroke risk factors, and other treatments, using a prospective cohort of people with small subcortical strokes from the SPS3 trial. LIMITS also aims to compare the efficacy of dual versus single antiplatelet therapy among participant groups with and without elevated baseline inflammatory marker levels for the outcome of a.) recurrent stroke, and b.) recurrent ischemic stroke, myocardial infarction, or death.
Old
Inflammation is increasingly recognized as playing a central role in atherosclerosis and coronary artery disease. And, peripheral blood markers of inflammation have been associated with incident and recurrent cardiac events. The relationship of these risk markers—which have the potential to be modified—to prognosis after ischemic stroke is less clear. The Levels of Inflammatory Markers in the Treatment of Stroke (LIMITS) study will address questions about the role of inflammatory markers in secondary stroke prevention in a cost-effective manner using the well-established framework of the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. The SPS3 trial is an ongoing Phase 3, multicenter secondary stroke prevention trial that focuses on preventing stroke recurrence in people with small vessel ischemic stroke, or lacunes. The overall purpose of the LIMITS study is to determine if serum levels of inflammatory markers—such as hsCRP, serum amyloid A (SAA), CD40 ligand (CD40L), and monocyte chemoattractant protein-1 (MCP-1)—predict recurrent stroke and other vascular events among people with a history of small artery ischemic stroke. The project will also determine if these markers predict which people will respond best to dual antiplatelet therapy with clopidogrel and aspirin. The specific aims of LIMITS are to determine if hsCRP, SAA, CD40L, and MCP-1 levels are independent risk factors for recurrent ischemic stroke, and for recurrent ischemic stroke, myocardial infarction, and death in participants in the SPS3 trial after adjusting for demographic and traditional stroke risk factors, and other treatments, using a prospective cohort of people with small subcortical strokes from the SPS3 trial. LIMITS also aims to compare the efficacy of dual versus single antiplatelet therapy among participant groups with and without elevated baseline inflammatory marker levels for the outcome of a.) recurrent stroke, and b.) recurrent ischemic stroke, myocardial infarction, or death.
The gender criteria for eligibility was updated to "All."
The eligibility criteria were updated.
New
Inclusion Criteria: - Patient must be randomized within 6 months of qualifying small subcortical stroke (S3) or subcortical TIA - One of the following lacunar syndromes: PMH; pure sensory stroke; sensorimotor stroke; ataxic hemiparesis; dysarthria; hemiballism; PMH with facial sparing, horizontal gaze palsy, contralateral III palsy, contralateral VI palsy; Ataxia with contralateral III palsy; pure dysarthria - Absence of cortical dysfunction (aphasia, apraxia, agnosia) - No ipsilateral cervical carotid stenosis (>= 50%) if S3 is hemispheric - No major-risk cardioembolic sources requiring anti-coagulation - MRI evidence of S3 that is >=2.0 cm in diameter if DWI/bright lesion on FLAIR/T2 or <=1.5cm hypointense lesion on FLAIR/T1, corresponding to the qualifying event (required for all brainstem events) OR multiple S3 in cerebral hemispheres of <=1.5cm hypointense lesions on FLAIR/T1 AND absence of cortical stroke and large subcortical stroke. Exclusion Criteria: - Disabling stroke (Ranking Scale >= 4) - Prior hemorrhagic stroke - Age <30 years - High risk of bleeding (recurrent GI or GU bleeding, active peptic ulcer disease, etc) - Need for long-term use of anticoagulants or other antiplatelet agents. - Prior cortical or retinal stroke / TIA - Prior ipsilateral carotid endarterectomy if hemispheric S3 - Impaired renal function: GFR<40 cc/min - Intolerance/contraindication to aspirin or clopidogrel - Adjusted Folstein MMSE <24 - Medical contraindication to MRI - Pregnancy or child-bearing potential without contraception - Other specific causes of stroke (e.g. dissection, vasculitis, drug abuse)
Old
Inclusion Criteria: - Patient must be randomized within 6 months of qualifying small subcortical stroke (S3) or subcortical TIA - One of the following lacunar syndromes: PMH; pure sensory stroke; sensorimotor stroke; ataxic hemiparesis; dysarthria; hemiballism; PMH with facial sparing, horizontal gaze palsy, contralateral III palsy, contralateral VI palsy; Ataxia with contralateral III palsy; pure dysarthria - Absence of cortical dysfunction (aphasia, apraxia, agnosia) - No ipsilateral cervical carotid stenosis (>= 50%) if S3 is hemispheric - No major-risk cardioembolic sources requiring anti-coagulation - MRI evidence of S3 that is >=2.0 cm in diameter if DWI/bright lesion on FLAIR/T2 or <=1.5cm hypointense lesion on FLAIR/T1, corresponding to the qualifying event (required for all brainstem events) OR multiple S3 in cerebral hemispheres of <=1.5cm hypointense lesions on FLAIR/T1 AND absence of cortical stroke and large subcortical stroke. Exclusion Criteria: - Disabling stroke (Ranking Scale >= 4) - Prior hemorrhagic stroke - Age <30 years - High risk of bleeding (recurrent GI or GU bleeding, active peptic ulcer disease, etc) - Need for long-term use of anticoagulants or other antiplatelet agents. - Prior cortical or retinal stroke / TIA - Prior ipsilateral carotid endarterectomy if hemispheric S3 - Impaired renal function: GFR<40 cc/min - Intolerance/contraindication to aspirin or clopidogrel - Adjusted Folstein MMSE <24 - Medical contraindication to MRI - Pregnancy or child-bearing potential without contraception - Other specific causes of stroke (e.g. dissection, vasculitis, drug abuse)
10 May '16
The description was updated.
New
Inflammation is increasingly recognized as playing a central role in atherosclerosis and coronary artery disease. And, peripheral blood markers of inflammation have been associated with incident and recurrent cardiac events. The relationship of these risk markers—which have the potential to be modified—to prognosis after ischemic stroke is less clear. The Levels of Inflammatory Markers in the Treatment of Stroke (LIMITS) study will address questions about the role of inflammatory markers in secondary stroke prevention in a cost-effective manner using the well-established framework of the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. The SPS3 trial is an ongoing Phase 3, multicenter secondary stroke prevention trial that focuses on preventing stroke recurrence in people with small vessel ischemic stroke, or lacunes. The overall purpose of the LIMITS study is to determine if serum levels of inflammatory markers—such as hsCRP, serum amyloid A (SAA), CD40 ligand (CD40L), and monocyte chemoattractant protein-1 (MCP-1)—predict recurrent stroke and other vascular events among people with a history of small artery ischemic stroke. The project will also determine if these markers predict which people will respond best to dual antiplatelet therapy with clopidogrel and aspirin. The specific aims of LIMITS are to determine if hsCRP, SAA, CD40L, and MCP-1 levels are independent risk factors for recurrent ischemic stroke, and for recurrent ischemic stroke, myocardial infarction, and death in participants in the SPS3 trial after adjusting for demographic and traditional stroke risk factors, and other treatments, using a prospective cohort of people with small subcortical strokes from the SPS3 trial. LIMITS also aims to compare the efficacy of dual versus single antiplatelet therapy among participant groups with and without elevated baseline inflammatory marker levels for the outcome of a.) recurrent stroke, and b.) recurrent ischemic stroke, myocardial infarction, or death.
Old
Inflammation is increasingly recognized as playing a central role in atherosclerosis and coronary artery disease. And, peripheral blood markers of inflammation have been associated with incident and recurrent cardiac events. The relationship of these risk markers—which have the potential to be modified—to prognosis after ischemic stroke is less clear. The Levels of Inflammatory Markers in the Treatment of Stroke (LIMITS) study will address questions about the role of inflammatory markers in secondary stroke prevention in a cost-effective manner using the well-established framework of the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. The SPS3 trial is an ongoing Phase 3, multicenter secondary stroke prevention trial that focuses on preventing stroke recurrence in people with small vessel ischemic stroke, or lacunes. The overall purpose of the LIMITS study is to determine if serum levels of inflammatory markers—such as hsCRP, serum amyloid A (SAA), CD40 ligand (CD40L), and monocyte chemoattractant protein-1 (MCP-1)—predict recurrent stroke and other vascular events among people with a history of small artery ischemic stroke. The project will also determine if these markers predict which people will respond best to dual antiplatelet therapy with clopidogrel and aspirin. The specific aims of LIMITS are to determine if hsCRP, SAA, CD40L, and MCP-1 levels are independent risk factors for recurrent ischemic stroke, and for recurrent ischemic stroke, myocardial infarction, and death in participants in the SPS3 trial after adjusting for demographic and traditional stroke risk factors, and other treatments, using a prospective cohort of people with small subcortical strokes from the SPS3 trial. LIMITS also aims to compare the efficacy of dual versus single antiplatelet therapy among participant groups with and without elevated baseline inflammatory marker levels for the outcome of a.) recurrent stroke, and b.) recurrent ischemic stroke, myocardial infarction, or death.
The eligibility criteria were updated.
New
Inclusion Criteria: - Patient must be randomized within 6 months of qualifying small subcortical stroke (S3) or subcortical TIA - One of the following lacunar syndromes: PMH; pure sensory stroke; sensorimotor stroke; ataxic hemiparesis; dysarthria; hemiballism; PMH with facial sparing, horizontal gaze palsy, contralateral III palsy, contralateral VI palsy; Ataxia with contralateral III palsy; pure dysarthria - Absence of cortical dysfunction (aphasia, apraxia, agnosia) - No ipsilateral cervical carotid stenosis (>= 50%) if S3 is hemispheric - No major-risk cardioembolic sources requiring anti-coagulation - MRI evidence of S3 that is >=2.0 cm in diameter if DWI/bright lesion on FLAIR/T2 or <=1.5cm hypointense lesion on FLAIR/T1, corresponding to the qualifying event (required for all brainstem events) OR multiple S3 in cerebral hemispheres of <=1.5cm hypointense lesions on FLAIR/T1 AND absence of cortical stroke and large subcortical stroke. Exclusion Criteria: - Disabling stroke (Ranking Scale >= 4) - Prior hemorrhagic stroke - Age <30 years - High risk of bleeding (recurrent GI or GU bleeding, active peptic ulcer disease, etc) - Need for long-term use of anticoagulants or other antiplatelet agents. - Prior cortical or retinal stroke / TIA - Prior ipsilateral carotid endarterectomy if hemispheric S3 - Impaired renal function: GFR<40 cc/min - Intolerance/contraindication to aspirin or clopidogrel - Adjusted Folstein MMSE <24 - Medical contraindication to MRI - Pregnancy or child-bearing potential without contraception - Other specific causes of stroke (e.g. dissection, vasculitis, drug abuse)
Old
Inclusion Criteria: - Patient must be randomized within 6 months of qualifying small subcortical stroke (S3) or subcortical TIA - One of the following lacunar syndromes: PMH; pure sensory stroke; sensorimotor stroke; ataxic hemiparesis; dysarthria; hemiballism; PMH with facial sparing, horizontal gaze palsy, contralateral III palsy, contralateral VI palsy; Ataxia with contralateral III palsy; pure dysarthria - Absence of cortical dysfunction (aphasia, apraxia, agnosia) - No ipsilateral cervical carotid stenosis (>= 50%) if S3 is hemispheric - No major-risk cardioembolic sources requiring anti-coagulation - MRI evidence of S3 that is >=2.0 cm in diameter if DWI/bright lesion on FLAIR/T2 or <=1.5cm hypointense lesion on FLAIR/T1, corresponding to the qualifying event (required for all brainstem events) OR multiple S3 in cerebral hemispheres of <=1.5cm hypointense lesions on FLAIR/T1 AND absence of cortical stroke and large subcortical stroke. Exclusion Criteria: - Disabling stroke (Ranking Scale >= 4) - Prior hemorrhagic stroke - Age <30 years - High risk of bleeding (recurrent GI or GU bleeding, active peptic ulcer disease, etc) - Need for long-term use of anticoagulants or other antiplatelet agents. - Prior cortical or retinal stroke / TIA - Prior ipsilateral carotid endarterectomy if hemispheric S3 - Impaired renal function: GFR<40 cc/min - Intolerance/contraindication to aspirin or clopidogrel - Adjusted Folstein MMSE <24 - Medical contraindication to MRI - Pregnancy or child-bearing potential without contraception - Other specific causes of stroke (e.g. dissection, vasculitis, drug abuse)
11 Feb '12
A location was updated in Mobile.
New
The overall status was removed for University of South Alabama.
A location was updated in Scottsdale.
New
The overall status was removed for Mayo Clinic Scottsdale.
A location was updated in Tucson.
New
The overall status was removed for University of Arizona Collage of Medicine.
A location was updated in La Jolla.
New
The overall status was removed for University of California, San Diego Medical Center.
A location was updated in Sacramento.
New
The overall status was removed for Sutter Neuroscience Institute.
A location was updated in Melbourne.
New
The overall status was removed for Melbourne Internal Medicine Associates.
A location was updated in Miami.
New
The overall status was removed for University of Miami.
A location was updated in Des Moines.
New
The overall status was removed for Mercy Medical Center.
A location was updated in Lexington.
New
The overall status was removed for University of Kentucky.
A location was updated in Boston.
New
The overall status was removed for Boston University Medical Center.
A location was updated in Detroit.
New
The overall status was removed for Wayne State University.
A location was updated in Detroit.
New
The overall status was removed for Henry Ford Health System.
A location was updated in Minneapolis.
New
The overall status was removed for Hennepin County Medical Center.
A location was updated in Rochester.
New
The overall status was removed for Mayo Clinic Rochester.
A location was updated in St. Louis.
New
The overall status was removed for St. John's Mercy Medical Center.
A location was updated in St. Louis,.
New
The overall status was removed for St. Louis University.
A location was updated in Camden.
New
The overall status was removed for Cooper University Hospital,.
A location was updated in New York.
New
The overall status was removed for Columbia University Medical Center.
A location was updated in Rochester.
New
The overall status was removed for University of Rochester Medical Center.
A location was updated in Rochester.
New
The overall status was removed for Rochester General Hospital.
A location was updated in West Haverstraw.
New
The overall status was removed for Helen Hayes Hospital.
A location was updated in Winston-Salem.
New
The overall status was removed for Wake Forest University Medical Center.
A location was updated in Cleveland.
New
The overall status was removed for Metro Health Medical Center.
A location was updated in Cleveland.
New
The overall status was removed for University Hospitals of Cleveland, Case Western Reserve University,Case Western Neurological Unit, 11100 Euclid Avenue, Lakeside 5508.
A location was updated in Portland.
New
The overall status was removed for Oregon Health and Science University.
A location was updated in Dallas.
New
The overall status was removed for University of Texas South Western Medical Center.
A location was updated in Houston.
New
The overall status was removed for The Methodist Hospital.
A location was updated in San Antonio.
New
The overall status was removed for University of Texas Health Science Center at San Antonio.
A location was updated in Marshfield.
New
The overall status was removed for Marshfield Clinic Research Foundation.
A location was updated in Milwaukee.
New
The overall status was removed for Medical College of Wisconsin.
A location was updated in Halifax.
New
The overall status was removed for Dalhousie University Center for Clinical Research.
A location was updated in Greenfield Park.
New
The overall status was removed for Hospital Charles LeMoyne Centre de recherché.
A location was updated in Montreal.
New
The overall status was removed for McGill University Health Center.
A location was updated in Santiago.
New
The overall status was removed for Pontificia Universidad Catolica de Chile.
A location was updated in Viña del Mar.
New
The overall status was removed for Hospital Naval Almirante Nef.
A location was updated in Guayaquil.
New
The overall status was removed for Hospital-Clinica Kennedy.
A location was updated in Guadalajara.
New
The overall status was removed for Universidad Autonoma de Guadalajara.
A location was updated in Mexico.
New
The overall status was removed for Instituto Nacional de Neurología y Neurocirugía.
A location was updated in Lima.
New
The overall status was removed for Hospital Nacional Alberto Sabogal.
A location was updated in Barcelona.
New
The overall status was removed for Hospital Germans Trias i Pujol,.
A location was updated in Barcelona.
New
The overall status was removed for Hospital del Mar.
A location was updated in Barcelona.
New
The overall status was removed for Hospital Dr. Josep Trueta.
A location was updated in Barcelona.
New
The overall status was removed for Hospital Clinico Universitario de Santiago de Compostela.
A location was updated in Barcelona.
New
The overall status was removed for Hospital del Sagrat Cor.
A location was updated in Barcelona.
New
The overall status was removed for Hospital Universitario de Bellvitge, Spain.